Trial
NCT01260103
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Burzynski Research Institute
Collaborators
—
Condition
Optic Nerve Glioma
Intervention
Temozolomide
Why stopped
Withdrawn: study halted prematurely, prior to enrollment of first participant
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-26